Raymond Chung, MD
Gastroenterology · Boston, MANPI 1154311769
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $27,032 of the $27,914 with a category attached, or 96.8%. GSK accounts for 63.1% of it on its own, with 6 other manufacturers making up the rest.
Across 18 payments — averaging $1550.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$18K
- Alnylam Pharmaceuticals Inc.$7K
- Immunocore Limited$2K
- Medtronic$532
- Vertex$500
- Johnson & Johnson$250
- plus $32 from 1 others
Across 149 payments — averaging $9104.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$695K
- GSK$281K
- Gilead$144K
- Janssen Research & Development, LLC$80K
- Bausch Health US, LLC$69K
- Merck$62K
- plus $25K from 4 others
What the payments were for
- Consulting fees$27,03297%
- Speaking & faculty fees$8503%
- Food & beverage$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 9 | $17,600 |
| Alnylam Pharmaceuticals Inc. | 4 | $6,600 |
| Immunocore Limited | 1 | $2,400 |
| Medtronic | 1 | $532 |
| Vertex | 1 | $500 |
| Johnson & Johnson | 1 | $250 |
| F. Hoffmann-la Roche AG | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KIMMTRAK$2,400
How this compares
$27,914 in reported general payments places this provider in the 85th percentile of 579 gastroenterology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 33 | $146,756 |
| VemlidyTenofovir Alafenamide | 42 | $58,784 |
| Entecavir | 47 | $22,377 |
| OzempicSemaglutide | 21 | $20,435 |
| Ursodiol | 56 | $12,135 |
| EliquisApixaban | 15 | $11,170 |
| Tacrolimus | 28 | $6,006 |
| Omeprazole | 96 | $2,338 |
| Lansoprazole | 13 | $1,564 |
| Tenofovir Disoproxil Fumarate | 20 | $1,454 |
| Azathioprine | 18 | $1,341 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 80 | $1,124 |
| Cyclosporine ModifiedCyclosporine, Modified | 13 | $1,039 |
| Nadolol | 17 | $785 |
| Famotidine | 13 | $349 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Boston
- Hiroyuki AiharaBoston$728K
- Jessica AllegrettiBoston$696K
- John LeungBoston$682K
- Ramnik XavierBoston$567K
- Adam CheifetzBoston$512K
- Carlo TraversoBoston$447K
- Tyler BerzinBoston$215K
- Marvin RyouBoston$162K
- Nneka UfereBoston$153K
- Christopher ThompsonBoston$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.